RISPERIDONE        SUPPORTING DATA 
Supporting data
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Risperidone monotherapy for acute mania (3)
Authors: Eerdekens, et al.
Title: Risperidone monotherapy in acute bipolar mania.
Reference: Poster presented at the 4th International Forum on Mood and Anxiety Disorders, November 2003.
Purpose: To determine the efficacy of risperidone monotherapy in the acute treatment of patients with a manic episode.
Study design: Randomized, double-blinded, placebo-controlled, 3-week, multicenter trial.
Follow up: 9 weeks open-label continuation following a 3-week acute phase.
Patients: 438 bipolar I inpatients (154 risperidone, 144 haloperidol, 140 placebo) with a manic episode (YMRS >20 and MADRS <20).
Treatment: Risperidone flexible dose (1–6 mg/day), haloperidol flexible dose (2 –12 mg/day), or placebo.
Results: Risperidone and haloperidol produced significantly greater improvements in YMRS scores compared with placebo from week 1 onwards. At the endpoint, response rates (>50% reduction in YMRS) were 48% for risperidone, 47% for haloperidol, and 33% for placebo (p < 0.05 versus placebo for both active treatments).  Symptoms of EPS were reported in 17% of risperidone-treated patients versus 40% of haloperidol-treated patients.
extra-pyramidal symptoms
Montgomery-Asberg Depression Rating Scale
Young Mania Rating Scale
Young Mania Rating Scale
Young Mania Rating Scale
Young Mania Rating Scale
Young Mania Rating Scale


 
  
home help sitemap acronyms help sitemap home